Navigation Links
Clinical Trial Shows Some Promise for Duchenne Muscular Dystrophy Drug
Date:7/18/2017

The results of an international clinical trial, led in part by a UC Davis School of Medicine expert, have shown that a drug therapy for a severe type of muscular dystrophy holds promise for a subgroup of patients.

In a paper just published online in the journal The Lancet, Craig McDonald and colleagues at 53 study sites in 18 countries describe the clinical benefit of using the drug ataluren for a certain group of patients carrying a specific “nonsense mutation” for Duchenne muscular dystrophy.

Duchenne muscular dystrophy is a rare but fatal genetic disorder characterized by progressive muscle degeneration and weakness, which is caused by an absence of dystrophin, a protein that helps keep muscle cells intact. The so-called nonsense mutation, a genetic mutation in the DNA sequence that results in a shorter, non-functional protein, is present in about 13 percent of Duchenne patients and makes the disease more severe.

McDonald and his co-authors say treatments focusing on dystrophin restoration, such as ataluren, are important because they can preserve existing muscle function, which otherwise progressively deteriorates.

“What’s very encouraging about these findings is that a treatment using ataluren for certain individuals with Duchenne muscular dystrophy may prompt a slowing or stabilizing of the disease progression and motor function that can be very meaningful to patients and provide them with invaluable, quality-of-life benefits,” said McDonald, who was the lead author on the study and serves as professor and chair of the UC Davis Department of Physical Medicine and Rehabilitation.

The study, a randomized, double-blind Phase 3 clinical trial, was sponsored by the New Jersey-based company that developed ataluren, PTC Therapeutics. It included 230 patients, half of whom received the drug therapy over a course of 48 weeks, and the other half who received a placebo.

To assess patient muscle function and mobility as well as drug efficacy, researchers used a six-minute walk test, which was developed by McDonald and his team at UC Davis. Duchenne study participants with the nonsense mutation who had a baseline six-minute walk of between 300 meters and under 400 meters were the subgroup of patients who were the most likely to see the clinical benefits of ataluren.

“While not all of the ataluren-treated participants reached statistical significance, this subgroup seems to represent a stage in the progression of disease where dystrophin restoration therapy, as measured by the six-minute walk test, does have value,” added McDonald, who has been a consultant to drug manufacturing companies working on therapies for Duchenne, including PTC Therapeutics. “Our findings certainly merit additional study because the patients and families I see in clinic every week are desperate for help.”

Duchenne muscular dystrophy primarily affects males. The lack of functional dystrophin protein affects the structural stability of skeletal, diaphragm and heart muscles. Patients with the disease lose the ability to walk as early as age 10 and experience life-threatening lung and heart complications in their late teens and twenties.

Of the approximately 250,000 people with the disorder worldwide, the nonsense mutation in Duchenne accounts for about 13 percent of cases, which represents approximately 2,000 patients in the U.S.

Read the full story at http://www.prweb.com/releases/2017/07/prweb14519391.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. Kidney Week 2013: New innovations in clinical science
2. Salar Joins Medical Informatics Experts to Judge AMIA’s First Ever Student Design Challenge: Reinventing Clinical Documentation
3. The DelRay Recovery Center Appoints Britt Bonner as the Director of Clinical Outreach
4. Clinical trial looks at impact of platelet-rich plasma therapy on tennis elbow
5. Nemours receives Dept. of Defense award to study physicians maintenance of optimal clinical program
6. Clinical trial finds concurrent therapy not necessary to achieve high pathological in breast cancer
7. Catalent’s Clinical Trial Supply Facility in Shanghai, China Opens for Business
8. Italian study examines clinical predictors of acute urinary symptoms after radiotherapy for prostate
9. Idol Lash: The Clinically Proven Eyelash Growth Enhancer Now Available in the Market With 1 Extra Bottle Offer
10. Paid Asthma Clinical Trial Now Enrolling at Achieve Clinical Research Near Birmingham, Alabama; Accepting M/F Patients with Asthma Age 12 - 75
11. Tinnitus Global Clinical Trials Review, H2, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2018)... ... 2018 , ... Convoy of Hope’s Disaster Services Team is currently in Marianna, ... set up to serve hurricane survivors with water, food, baby products, hygiene kits, flood ... additional truckloads of supplies are in motion to Florida. , Convoy’s walk-up ...
(Date:10/13/2018)... , ... October 13, 2018 , ... ... on Sports, Fitness & Nutrition, has announced LaRhonda Burley as its new Vice ... congressionally chartered in 2010 to support and strengthen the mission of the President's ...
(Date:10/11/2018)... ... October 11, 2018 , ... The Danisco Foundation today has ... their fields recognized by DuPont Nutrition & Health for scientific excellence and a ... of food, nutrition and health. , This year’s medalists are: , ? DuPont ...
(Date:10/11/2018)... ... October 11, 2018 , ... Four weeks before the ... warns former U.S. Department of Homeland Security deputy assistant secretary Paul Rosenzweig in ... Can Stop it. , Pointing to the ability of Russian hackers to gain ...
(Date:10/7/2018)... ... 07, 2018 , ... Guruji Mahendra Trivedi is an innovative ... practical and spiritual levels. Founder of the Trivedi Effect®, Guruji Mahendra Trivedi will ... by Navratri, is a mystical time when Divine Energy is at its peak ...
Breaking Medicine News(10 mins):
(Date:10/20/2018)... ... , ... Dr. Rajdeep S. Randhawa of Innovative Dentistry has been reviewed ... and Restorative Dentistry’ which includes an exclusive group of 6 Top Dentists out ... dentist website. Dr. Randhawa has been practicing dentistry since 1988 and specializes in ...
(Date:10/18/2018)... CLEARWATER, Fla. (PRWEB) , ... October 18, 2018 ... ... platform dedicated to simplifying the process of buying insurance, announced today the launch ... EZ-App was developed by Ensurem as part of its mission to streamline the ...
(Date:10/17/2018)... ... 17, 2018 , ... Dr. Dan Holtzclaw, Chief Clinical Officer ... use of placental based growth factors for the treatment of nerve injuries related ... DIA Dental Implant Center locations in Austin and San Antonio, we occasionally see ...
Breaking Medicine Technology: